Drug Evaluation Committee Paper on the Implementation of eConsent and Strategies for Addressing Challenges
August 2023
In January 2022, the International Trials Department of the National Center for Global Health and Medicine led an online survey on eConsent targeting member companies of the Japan Pharmaceutical Manufacturers Association.
Based on the results of that survey, the idea of publishing a paper on the implementation of eConsent and strategies for addressing challenges was discussed. The International Trials Division of the National Center for Global Health and Medicine and the Electronic Standard for Medical Information Expert CommitteeTF3 jointly authored the paper, which has now been submitted to, accepted by, and published in GHM Open.
▼Available on J-STAGE
We hope to provide feedback to the member companies of the Japan Pharmaceutical Manufacturers Association who participated in our survey. Furthermore, through this publication, we hope to foster discussions regarding eConsent not only among pharmaceutical companies but also among all stakeholders involved in clinical trials, thereby promoting clinical trials that are more patient-centered.
We hope this publication will help streamline clinical trials in the pharmaceutical industry and support the widespread adoption of eConsent.
Japan Pharmaceutical Manufacturers Association, Drug Evaluation Committee,
Electronic Standard for Medical Information Expert Committee, FY2023 Task Force 3